{"id":477457,"date":"2020-04-02T12:32:01","date_gmt":"2020-04-02T12:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=477457"},"modified":"2020-04-02T12:32:01","modified_gmt":"2020-04-02T12:32:01","slug":"retinitis-pigmentosa-market-insight-market-size-epidemiology-leading-companies-emerging-and-marketed-therapies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/retinitis-pigmentosa-market-insight-market-size-epidemiology-leading-companies-emerging-and-marketed-therapies_477457.html","title":{"rendered":"Retinitis Pigmentosa Market Insight, Market Size, Epidemiology, Leading Companies, Emerging and Marketed Therapies"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Retinitis Pigmentosa Market Insight, Market Size, Epidemiology, Leading Companies, Emerging and Marketed Therapies\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Retinitis Pigmentosa Market Insight, Market Size, Epidemiology, Leading Companies, Emerging and Marketed Therapies\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cRetinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the Retinitis Pigmentosa , historical and forecasted epidemiology as well as the Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/retinitis-pigmentosa-market\">DelveInsight has launched a new report on Retinitis Pigmentosa Market Insights, Epidemiology and Market Forecast-2030 <\/a><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;<strong>Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2030<strong>&#8220;<\/strong><\/strong>&nbsp;report delivers an in-depth understanding of the Retinitis Pigmentosa , historical and forecasted epidemiology as well as the Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Retinitis Pigmentosa market report provides current treatment practices, emerging drugs, Retinitis Pigmentosa market share of the individual therapies, current and forecasted Retinitis Pigmentosa market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Retinitis Pigmentosa treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key benefits of the report<br \/> <\/strong>1. Retinitis Pigmentosa market report covers a descriptive overview and comprehensive insight of the Retinitis Pigmentosa epidemiology and Retinitis Pigmentosa market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.) <br \/> 2. Retinitis Pigmentosa market report provides insights on the current and emerging therapies.<br \/> 3. Retinitis Pigmentosa market report provides a global historical and forecasted market covering drug outreach in 7 MM. <br \/> 4. Retinitis Pigmentosa market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Retinitis Pigmentosa market.<\/p>\n<p style=\"text-align: justify;\">Request for sample pages here <strong>-&gt;<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/retinitis-pigmentosa-market\">https:\/\/www.delveinsight.com\/sample-request\/retinitis-pigmentosa-market<\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Key points of the report:-<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Retinitis Pigmentosa Market Size in the 7MM was found to be USD 237.27 million in 2017.<\/li>\n<li>Among the 7MM countries, the United States had the highest market size of 56.40% of the total market in 2017.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;Drugs covered<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <\/strong>HORA-RPE65<\/li>\n<li><strong>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <\/strong>jCell<\/li>\n<li><strong>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <\/strong><strong>AGN-151597<\/strong><\/li>\n<li><strong>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <\/strong><strong>Cenegermin <\/strong><\/li>\n<li><strong>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <\/strong>Renexus<\/li>\n<li><strong>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <\/strong>hRPC<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">And many others<\/p>\n<p style=\"text-align: justify;\"><strong>The key players in <\/strong>Retinitis Pigmentosa <strong>market are:<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Horama<\/li>\n<li>jCyte<\/li>\n<li><strong>Allergan<\/strong><\/li>\n<li><strong>Domp&eacute; Farmaceutici<\/strong><\/li>\n<li>Neurotech Pharmaceuticals<\/li>\n<li>ReNeuron Limited<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">And many others<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Reimbursement Scenario <\/strong><\/p>\n<p style=\"text-align: justify;\">Novartis Pharmaceuticals UK has a commercial arrangement with NHS England making the treatment available to the NHS at a discount, the size of which is commercial in confidence.<\/p>\n<p style=\"text-align: justify;\">The Spark therapeutics provides commercial and governance insurance option such as co-pay and if a patient has government insurance, Spark Therapeutics Generation Patient Services can refer them to independent nonprofit 501(c)(3) organizations that may be able to help with out-of-pocket costs.<\/p>\n<p style=\"text-align: justify;\"><strong>KOL- Views <\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The high unmet needs associated with the disease have driven vendors to conduct R&amp;D, which has fueled the pipeline for Retinitis Pigmentosa treatment.<\/li>\n<li>Gene therapy is a relatively safe means of treatment and is likely to become even safer as the technology for vector delivery advances.<\/li>\n<li>The main causes of the late detection of Retinitis Pigmentosa is lack of awareness and ignorance among the patients.&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of contents<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1. Report Introduction<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>2. Retinitis Pigmentosa Market Overview at a Glance<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>3. Retinitis Pigmentosa Disease Background and Overview<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>4. Retinitis Pigmentosa Epidemiology and Patient Population<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>5. Retinitis Pigmentosa Country-Wise Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>6.1 United States<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>6.2. EU&ndash;5<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>6.3. Germany<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>6.4. France<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>6.5. Italy<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>6.6. Spain<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>6.7. United Kingdom<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>6.8. Japan<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>7. Retinitis Pigmentosa Treatments &amp; Medical Practices<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>8. Retinitis Pigmentosa Emerging Therapies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>9. Key Cross Competition<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>9.1. <\/strong>HORA-RPE65 (Horama)<\/p>\n<p style=\"text-align: justify;\"><strong>9.2. &nbsp;<\/strong>jCell (jCyte)<\/p>\n<p style=\"text-align: justify;\"><strong>9.3. AGN-151597: Allergan<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>9.4 Cenegermin: Domp&eacute; Farmaceutici<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>9.5 <\/strong>Renexus (Neurotech Pharmaceuticals)<\/p>\n<p style=\"text-align: justify;\"><strong>9.6 <\/strong>hRPC (ReNeuron Limited)<\/p>\n<p style=\"text-align: justify;\"><strong>10. Retinitis Pigmentosa Market Size<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>11. 7MM Retinitis Pigmentosa Country-Wise Market Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>12. United States Market Size<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>13. EU5 Market Size<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>13.1. Germany Market Size<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>13.2. France Market Size<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>13.3. United Kingdom Market Size<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>13.4. Spain Market Size<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>13.5. Italy Market Size<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>14. Japan Market Size<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>15. Retinitis Pigmentosa Report Methodology<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>16. DelveInsight Capabilities<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>17. Disclaimer<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>18. About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">Request for sample pages here <strong>-&gt;<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/retinitis-pigmentosa-market\">https:\/\/www.delveinsight.com\/sample-request\/retinitis-pigmentosa-market<\/a><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/retinitis-pigmentosa-epidemiology\" target=\"_blank\">Retinitis&nbsp;Pigmentosa&nbsp;&#8211; Epidemiology Forecast to 2030<\/a><\/p>\n<p class=\"posttext\" style=\"text-align: justify;\">DelveInsight&#8217;s Retinitis Pigmentosa Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Retinitis Pigmentosa in the United States, EU5, Japan.<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/retinitis-pigmentosa-pipeline-insight\" target=\"_blank\">Retinitis&nbsp;Pigmentosa&nbsp;&#8211; Pipeline Insights, 2020<\/a><\/p>\n<p class=\"posttext\" style=\"text-align: justify;\">Retinitis Pigmentosa Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Retinitis Pigmentosa market.<\/p>\n<p class=\"posttext\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=retinitis-pigmentosa-market-insight-market-size-epidemiology-leading-companies-emerging-and-marketed-therapies\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=retinitis-pigmentosa-market-insight-market-size-epidemiology-leading-companies-emerging-and-marketed-therapies\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight DelveInsight\u2019s \u201cRetinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the Retinitis Pigmentosa , historical and forecasted epidemiology as well as the Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/retinitis-pigmentosa-market-insight-market-size-epidemiology-leading-companies-emerging-and-marketed-therapies_477457.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-477457","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/477457","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=477457"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/477457\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=477457"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=477457"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=477457"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}